Evidence map›Paper›PMID 33324572›Full record

ReviewFrontiers in cellular and infection microbiology2020

Gut Microbiota Status in COVID-19: An Unrecognized Player?

Sabrina Donati Zeppa, Deborah Agostini, Giovanni Piccoli, Vilberto Stocchi, Piero Sestili

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Altered gut microbiome in convalescent patients with coronavirus disease 2019.Frontiers in cellular and infection microbiology · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. A new capacity of gut microbiota: Fermentation of engineered inorganic carbon nanomaterials into endogenous organic metabolites.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sabrina Donati ZeppaDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Deborah AgostiniDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Giovanni PiccoliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Vilberto StocchiDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.
Piero SestiliDepartment of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection with the SARS-CoV-2 virus causes cardiopulmonary and vascular complications, ranging in severity. Understanding the pathogenic mechanisms of the novel SARS-CoV2 infection and progression can provide potential novel targets for its prevention and/or treatment. Virus microbiota reciprocal interactions have been studied in a variety of viral infections. For example, the integrity of Coronavirus particles can be disrupted by surfactin, a bacterial surface molecule that targets other viruses, including that of influenza A. In this light, intestinal microbiota likely influences COVID-19 virulence, while from its side SARS-CoV-2 may affect the intestinal microbiome promoting dysbiosis and other deleterious consequences. Hence, the microbiota pre-existing health status and its alterations in the course of SARS-CoV-2 infection, are likely to play an important, still underscored role in determining individual susceptibility and resilience to COVID-19. Indeed, the vast majority of COVID-19 worst clinical conditions and fatalities develop in subjects with specific risk factors such as aging and the presence of one or more comorbidities, which are intriguingly characterized also by unhealthy microbiome status. Moreover, these comorbidities require complex pharmacological regimens known as "polypharmacy" that may further affect microbiota integrity and worsen the resilience to viral infections. This complex situation may represent a further and underestimated risk with regard to COVID-19 clinical burden for the elderly and comorbid people. Here, we discuss the possible biological, physiopathological, and clinical implications of gut microbiota in COVID-19 and the strategies to improve/maintain its healthy status as a simple and adjunctive strategy to reduce COVID-19 virulence and socio-sanitary burden.

Indexed as

Age FactorsCOVID-19COVID-19 Drug TreatmentDysbiosisGastrointestinal MicrobiomeGastrointestinal TractHumansMicrobial InteractionsRisk FactorsSARS-CoV-2VirulenceCOVID-19gut-lung axisgut microbiotamicrobiota manipulatingmicrobiota-virus interactionspolypharmacypreventive therapeutic strategiesSARS-CoV-2

Identifiers

PMID33324572
PMCPMC7725702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.